Abstract
Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent.
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Humans
-
Neoplasms / blood supply*
-
Neoplasms / drug therapy*
-
Neovascularization, Pathologic / drug therapy*
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab